ASX:CTECryosite Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cryosite Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume418 shsAverage VolumeN/AMarket Capitalization$2.81 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartInsider TradesHeadlines Cryosite Limited provides long term storage and supply chain logistics management of pharmaceutical products used in clinical trials and biological materials in Australia. It operates in two segments, Cord Blood and Tissues Storage, and Clinical Trials Logistics and Biorepository. The Cord Blood and Tissues Storage segment provides long term storage for cord blood and tissue samples. The Clinical Trials Logistics and Biorepository segment offers biorepository services; clinical trials logistics; commercial drug distribution; and other storage and distribution based services, including the importation and distribution of laboratory diagnostic products. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was founded in 1999 and is based in South Granville, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cryosite. Previous Next 2.9 Community Rank Outperform VotesCryosite has received 11 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCryosite has received 8 “underperform” votes. (Add your “underperform” vote.)Community SentimentCryosite has received 57.89% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cryosite and other stocks. Vote “Outperform” if you believe CTE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCryosite does not currently pay a dividend.Dividend GrowthCryosite does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cryosite insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cryosite is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cryosite is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.58 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolASX:CTE Previous Symbol CUSIPN/A CIKN/A Webhttp://www.cryosite.com/ Phone61 2 8865 2000Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio1.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$8.14 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.55 Book ValueA($0.01) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees23 Outstanding Shares46,859,600Market Cap$2.81 million Next Earnings DateN/A OptionableNot Optionable Receive CTE News and Ratings via Email Sign-up to receive the latest news and ratings for CTE and its competitors with MarketBeat's FREE daily newsletter. Cryosite (ASX:CTE) Frequently Asked Questions Has Cryosite been receiving favorable news coverage? Media stories about CTE stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cryosite earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutCryosite. Who are some of Cryosite's key competitors? Some companies that are related to Cryosite include Deepmatter Group (DMTR), Genedrive (GDR), Dorsavi (DVL), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG), Smiles Inclusive (SIL), Imaging Dynamics (IDL), Lifespot Health (LSH), 3D Signatures (DXD), Med Biogene (MBI), BioMark Diagnostics (BUX), Carl Data Solutions (CRL), EPIGENOMICS AG/S (EPGNY), Eternity Healthcare (ETAH) and Imagin Medical (IME). Who are Cryosite's key executives? Cryosite's management team includes the following people: Mr. Bryan Dulhunty BEc, ACA, Exec. Chairman & Company Sec.Mr. Mark Edmund Payton Byrne, Chief Exec. Officer What is Cryosite's stock symbol? Cryosite trades on the ASX under the ticker symbol "CTE." How big of a company is Cryosite? Cryosite has a market capitalization of $0.00 and generates $8.14 million in revenue each year. Cryosite employs 23 workers across the globe. View additional information about Cryosite. What is Cryosite's official website? The official website for Cryosite is http://www.cryosite.com/. How can I contact Cryosite? The company can be reached via phone at 61 2 8865 2000. This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: What is a balanced fund?
